Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes

Cancer Research

Volumn 58, Issue 14, 1998, Pages 3087-3093

  Van Hall, Thorbald ^a   Van De Rhee, Nastasja E ^a   Schoenberger, Stephen P ^a   Vierboom, Michel P M ^a   Verreck, Frank A W ^a   Melief, Cornelis J M ^a   Offringa, Rienk ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; PROTEIN P53; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; LONG TERMINAL REPEAT; MONKEY; MOUSE; NONHUMAN; ONCOGENE H RAS; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; TUMOR CELL LINE; VACCINE PRODUCTION; WART VIRUS;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CLONING, MOLECULAR; EPITOPES; IMMUNODOMINANT EPITOPES; MICE; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PLASMIDS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VACCINES, DNA;

EID: 0032527901     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Melief, C. J. M. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res., 58: 143-175, 1992.
2. Boon, T., Cerottini, J-C., van den Eynde, B., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
3. Jaffe, M. J., and Pardoll, D. M. Murine tumor antigens: is it worth the search? Curr. Opin. Immunol., 8: 622-627, 1996.
4. Melief, C. J. M., Offringa, R., Toes, R. E. M., and Kast, W. M. Peptide-based cancer vaccines. Curr. Opin. Immunol., 8: 651-657, 1996.
5. Toes, R. E. M., Offringa, R., Feltkamp, M. C. W., Visseren, M. J. W., Schoenberger, S. P., Melief, C. J. M., and Kast, W. M. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst. Mitt., 94: 72-86, 1994.
6. Feltkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minnaar, R. P., De Jongh, B. M., Drijfhout, J. W., Ter Schegget, J., Melief, C. J. M., and Kast, W. M. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2242-2249, 1993.
7. Feltkamp, M. C. W., Vreugdenhil, G. R., Vierboom, M. P. M., Ras, E., Van der Burg, S. H., Ter Schegget, J., Melief, C. J. M., and Kast, W. M. CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol., 25: 2638-2641, 1995.
8. Vierboom, M. P. M., Nijman, H. W., Offringa, R., van der Voort, E. I. H., van Hall, T., van den Broek, L., Fleuren, G., Kenemans, P., Kast, W. M., and Melief, C. J. M. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med., 186: 695-704, 1997.
9. Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., Van der Eb, A. J., and Melief, C. J. M. Eradication of adenovirus E1-induced tumors by E1a-specific cytotoxic T lymphocytes. Cell, 59: 603-615, 1989.
10. Van der Eb, A. J., and Graham, F. L. Assay of transforming activity of tumor virus DNA. Methods Enzymol., 654: 826-839, 1980.
11. Kaczmarek, L., Oren, M., and Baserga, R. Co-operation between the p53 protein tumor antigen and platelet-poor plasma in the induction of cellular DNA synthesis. Exp. Cell Res., 162: 268-272, 1986.
12. Reddy, E. P., Lipman, D., Anderson, P. R., Tronick, S. R., and Aaronson, S. A. Nucleotide sequence analysis of the BALB/c murine sarcoma virus transforming gene. J. Virol., 53: 984-987, 1985.
13. Van Beveren, C., van Straaten, F., Curran, T., Muller, R., and Verma, I. M. Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell, 32: 1241-1255, 1983.
14. Toes, R. E. M., Offringa, R., Blom, H. J. J., Brandt, R. M. P., Van der Eb, A. J., Melief, C. J. M., and Kast, W. M. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J. Immunol., 154: 3396-3405, 1995.
15. Sijts, E. J. A. M., Ossendorp, F., Mengedé, E. A. M., Van den Elsen, P. J., and Melief, C. J. M. An immunodominant MCF murine leukemia virus encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV type specificity of MCF-directed CTL. J. Immunol., 152: 106-116, 1994.
16. Karttunen, J., and Shastri, N. Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc. Natl. Acad. Sci. USA, 88: 3972-3976, 1991.
17. Sanderson, S., and Shastri, N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol., 6: 1994.
18. Traversari, C., van der Bruggen, P., van den Eynde, B., Hainaut, P., Lemoine, C., Ohta, N., Old, L., and Boon, T. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologuous CTL. Immunogenetics, 35: 145-152, 1992.
19. Rammensee, H. G., Friede, T., and Stevanovic, S. MHC ligands and peptide motifs: first listing. Immunogenetics, 41: 178-228, 1995.
20. Christy, R. J., and Huang, R. C. C. Functional analysis of the long terminal repeats of intracisternal A-particle genes: sequences within th U3 region determine both the efficiency and direction of promoter activity. Mol. Cell. Biol., 8: 1093-1102, 1988.
21. Donnelly, J. J., Ulmer, J. B., Shiver, J. W., and Liu, M. A. DNA vaccines. Annu. Rev. Immunol., 15: 617-648, 1997.
22. Bullock, T. N. J., and Eisenlohr, L. C. Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames. J. Exp. Med., 184: 1319-1329, 1996.
23. Bullock, T. N. J., Patterson, A. E., Franlin, L. L., Notidis, E., and Eisenlohr, L. C. Initiation codon scanthrough versus termination codon readthrough demonstrates strong potential for major histocompatibility complex class I-restricted cryptic epitope expression. J. Exp. Med., 186: 1051-1058, 1997.
24. Elliott, T., Bodmer, H., and Townsend, A. Recognition of out-of-frame major histocompatibilily complex class I-restricted epitopes in vivo. Eur. J. Immunol., 26: 1175-1179, 1996.
25. 2 terminus of the nucleoprotein gene does not affect generation of cytotoxic T lymphocyte epitopes. J. Immunol., 147: 2697-2705, 1991.
26. Wang, R., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., and Rosenberg, S. A. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med., 183: 1131-1140, 1996.
27. Guilloux, Y., Lucas, S., Brichard, V. G., Van Pel, A., Viret, C., De Plaen, E., Brasseur, F., Lethe, B., Jotereau, F., and Boon, T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferese V gene. J. Exp. Med., 183: 1173-1183, 1996.
28. Coulie, P. G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Boon, T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Aca. Sci. USA, 92: 7976-7980, 1995.
29. Malarkannan, S., Afkarian, M., and Shastri, N. A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells. J. Exp. Med., 182: 1739-1750, 1995.
30. Malarkannan, S., Gonzalez, F., Nguyen, V., Adair, G., and Shastri, N. Alloreactive CD8+ T cells can recognize unusual, rare, and unique processed peptide/MHC complexes. J. Immunol., 157: 4464-4473, 1996.
31. Mayrand, S., Schwarz, D. A., and Green, W. R. An alternative translational reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus. J. Immunol., 160: 39-50, 1998.
32. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., Deleo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence of T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
33. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J. M., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.
34. Appleman, L., Uyeki, J., and Frey, A. B. Mouse embryo fibroblasts transformed by activated ras or dominant-negative p53 express cross-reactive tumor rejection antigens. Int. J. Cancer, 61: 887-894, 1995.
35. Ehrlich, T., Wishniak, O., Isakov, N., Cohen, O., Segal, S., Rager-Zisman, B., and Gopas, J. The effect of H-ras expression on tumorigenicity and immunogenicity of Balb/c 3T3 fibroblasts. Immunol. Lett., 39: 3-8, 1994.
36. Spooner, R. A., Deonarain, M. P., and Epenetos, A. A. DNA vaccination for cancer treatment. Gene Ther., 2: 173-180, 1995.
37. Nabel, G. J., Nabel, E. G., Yang, Z., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., and Chang, A. E. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA, 90: 11307-11311, 1993.
38. Nabel, G. J., Gordon, D., Bishop, D. K., Nickoloff, B. J., Yang, Z., Aruga, A., Cameron, M. J., Nabel, E. G., and Chang, A. E. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA, 93: 15388-15393, 1996.